Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYBR CyberCare the new look of healthcare -- Ignore unavailable to you. Want to Upgrade?

To: Murray_Mac who wrote (1947)	5/25/2000 12:04:00 PM
From: Tadsamillionaire	Read Replies (1) \| Respond to of 3392

New Target Price./////// Moneyclip-picks.com Speculative Equities Investing. Last updated 21/05/00 Moneyclip-picks.com is a site which provides editorial commentary to its readers on small and microcap stocks. The primary focus of the site is to identify undervalued and emerging technology companies while their prices are still attractive. The site is updated with new picks on Sundays. The material provided on this site is to be viewed as editorial commentary on selected equity issues and should not in any way be interpreted as a recommendation to buy, said securities. Moneyclip-picks.com in no way assumes any responsibility and/or liability for the investment choices of our readers. The Editor. Now that our responsibilities have been fulfilled...lets move on. *NEW PICK* (CYBR) CyberCare, Fridays close $8.19 USD, however traded below $7.00 afterhours. CYBR is in the business of distance medicine and has developed a web enabled product called EHC, or Electronic House Call system which allows qualified medical professionals to examine patients remotely. The target market for the product is HUGE and cost savings related to it deployment enormous. The product is market ready and awaiting FDA approval due out any week now. There is currently a short position in excess of 4 million shares and the company has been subjected to numerous short/basher attacks and negative media which have proven to be largely without substance. On Friday after the bell three lawsuits were launched, by former shareholders accusing the company of issuing misleading press releases and requesting damages for market loses. For all intents and purposes these legal claims and negative madia appear without merit. CYBR has not been charged with anything to date and the FDA review process remains intact. We believe Friday's lawsuits to be the final tactic of this highly orchestrated short campaign against the company and Monday could present a very attractive entry point.... Target $24.00 six months $50.00 one year. I am still long on CYBR....